| |FEBRUARY 20269SUN PHARMA'S NOVELTREAT GETS DCGI APPROVAL FOR WEIGHT LOSSBAYER AND VANDERBILT TO SPEED UP CARDIOVASCULAR AND KIDNEY TREATMENTSBayer and Vanderbilt University Medical Center (VUMC) have launched a five-year collaboration focused on fast-tracking the development of new therapies for cardiovascular and kidney diseases.The medical requirements in these regions are very high and unmet and thus this partnership is even more important.It will be based on the advanced research platform of the VUMC, including its BioVU repository of DNA and plasma samples, to create useful data that will acceler-ate the process of finding and developing possible treat-ments. Bayer will provide its long-standing experience in drug discovery and translational science, whereas VUMC will provide its profound preclinical and clinical experience."We are thrilled to partner with VUMC to bring cut-ting-edge science and real-world data to accelerate the development of innovative treatments," said Juergen Eckhardt, Head of Business Development and Licensing at Bayer Pharmaceuticals. "This collaboration reflects our shared vision to bring precision medicine to pa-tients faster."Ken Holroyd, Vice President for Tech Transfer at VUMC, added, "VUMC's recognized research faculty and unique data resources will perfectly complement Bay-er's expertise in pharmaceutical discovery, enabling us to transform research into impactful new treatments for patients."This strategic alliance highlights the intentions of the two institutions to promote precision medicine and overcome severe health issues in cardiovascular and kidney diseases. POSun Pharmaceutical Industries has announced it has received approval from the Drugs Controller General of India (DCGI) for Noveltreat, a generic version of semaglutide injection.This licence paves the way to a new, low-priced alternative in weight management therapy of the Indian patients. The Noveltreat also aims at helping individuals with obesity and associated cases to lose weight.Novo Nordisk originally developed semaglutide but it has caught the interest of people all over the world due to its great ability to assist people in losing weight. At Noveltreat, Sun Pharma is trying to offer an alternative to the branded version of the product at a lower price without compromising benefits. The mechanism of action of the drug is that it mimics a hormone that assists in the regulation of blood sugar and appetite making the user easy to control their weight.Noveltreat by Sun Pharma will be offered in pre-filled and injected in a pen, which is easy to administer at home. The firm believes in enhancing access to affordable healthcare and it hopes to have a drastic effect in the rising obesity issue in India.Sun Pharma's Noveltreat will be available in a pre-filled pen for self-injection, making it convenient for patients to use at home. The company is committed to improving access to affordable healthcare and hopes to make a significant impact on the growing obesity crisis in India."We are pleased to receive approval for Noveltreat, which will provide patients with a proven treatment for weight management," said a company spokesperson. With the approval in place, Sun Pharma is now preparing for the launch of Noveltreat, offering a promising new solution to those looking to manage their weight more effectively. PO
< Page 8 | Page 10 >